All In Biotech

Drug Trial Radar · NCT07841210

Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors

An Exploratory Study of Fosrolapitant and Palonosetron Hyerocthoride for the Prevention of Nausea and Vomiting Induced by Highly Emetogenic ADC Therapy in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Actual

Start

Sep 14, 2026

Primary completion

Jan 31, 2028

Study completion Jan 31, 2028

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Nanyang Central Hospital; Hubei Cancer Hospital
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by highly emetogenic antibody-drug conjugate (ADC) therapy in patients with solid tumors. A total of 60 patients are planned to be enrolled and divided into two groups: Group A will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone plus Olanzapine, and Group B will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone.

Conditions

  • Solid Tumor Cancer

Interventions

  • Fosrolapitant and Palonosetron; Dexamethasone; OlanzapineDrug

    HR20013 IV on D1; Dexamethasone 12 mg PO QD on D1, 3.75 mg PO BID on D2-4; Olanzapine 5 mg PO on D1-4

  • Fosrolapitant and Palonosetron; DexamethasoneDrug

    HR20013 IV on D1; Dexamethasone 12 mg PO QD on D1, 3.75 mg PO BID on D2-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving complete response (CR) during Days 0-21 after study drug administration in Cycle 1 (defined as no emetic episodes and no rescue medication use).Time frame: Day 0-21 after first treatment cycle 1 dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.